Other research analysts also recently issued research reports about the stock. Piper Jaffray Cos. set a $95.00 price objective on shares of Bluebird Bio and gave the stock a buy rating in a report on Thursday, September 8th. Goldman Sachs Group Inc. restated a buy rating and set a $135.00 price objective on shares of Bluebird Bio in a report on Thursday, September 8th. Maxim Group restated a buy rating and set a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a report on Thursday, August 4th. BTIG Research restated a buy rating and set a $72.00 price objective on shares of Bluebird Bio in a report on Wednesday, June 29th. Finally, Jefferies Group restated a buy rating and set a $80.00 price objective on shares of Bluebird Bio in a report on Friday, July 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $91.60.
Bluebird Bio (NASDAQ:BLUE) traded up 0.58% during midday trading on Friday, hitting $56.90. The stock had a trading volume of 826,483 shares. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $99.70. The stock’s 50 day moving average price is $63.71 and its 200-day moving average price is $50.93. The company’s market cap is $2.11 billion.
Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. During the same quarter in the previous year, the firm posted ($1.57) EPS. The business’s revenue for the quarter was down 68.6% compared to the same quarter last year. Equities research analysts predict that Bluebird Bio will post ($6.19) earnings per share for the current year.
In other news, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the transaction, the insider now directly owns 4,656 shares in the company, valued at $209,706.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.50% of the company’s stock.
Several large investors have recently bought and sold shares of BLUE. Wellington Management Group LLP acquired a new stake in Bluebird Bio during the first quarter worth $51,095,000. BlackRock Inc. increased its stake in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares during the period. California State Teachers Retirement System increased its stake in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock worth $3,363,000 after buying an additional 1,682 shares during the period. Swiss National Bank increased its stake in Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock worth $2,585,000 after buying an additional 5,700 shares during the period. Finally, Iguana Healthcare Management LLC acquired a new stake in Bluebird Bio during the first quarter worth $1,030,000.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.